Amount of cost reimbursement received recorded as a reduction of research and development expenses.

No definition available.

Name:	avbp_ArrangementCostReimbursementReceived
Namespace Prefix:	avbp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Maximum amount payable upon achievement of certain clinical and regulatory milestone events.

+ References

No definition available.

+ Details

Name:	avbp_ArrangementMaximumPaymentClinicalAndRegulatoryMilestones
Namespace Prefix:	avbp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Maximum amount payable upon achievement of commercial milestones.

+ References

No definition available.

+ Details

Name:	avbp_ArrangementMaximumPaymentCommercialMilestones
Namespace Prefix:	avbp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of cash outflow for cash payment made in relation to the agreement.

+ References

No definition available.

+ Details

Name:	avbp_ArrangementNonRefundableCashPayment
Namespace Prefix:	avbp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of milestone payments made during the period. May include clinical, regulatory and commercial milestone payments.

+ References

No definition available.

+ Details

Name:	avbp_ArrangementPaymentsMilestones
Namespace Prefix:	avbp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of shares issued in lieu of cash in execution of agreement.

+ References

No definition available.

+ Details

Name:	avbp_StockIssuedDuringPeriodSharesIssuedInExecutionOfAgreement
Namespace Prefix:	avbp_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=avbp_CollaborativeArrangementGlobalTechnologyTransferAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avbp_ShanghaiAllistPharmaceuticalsCo.Ltd.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=avbp_CollaborativeArrangementClinicalCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments, Contingencies, and Collaborations - Allist (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Jun. 30, 2021	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025
Agreement
Research and development		$ 37,617	$ 61,289
Global Technology Transfer And License Agreement \| Allist
Agreement
Cash payment	$ 40,000
Maximum amount payable upon achievement of certain clinical and regulatory milestone events		105,000
Maximum amount payable upon achievement of commercial milestones		655,000
Global Technology Transfer And License Agreement \| Allist \| Common stock
Agreement
Shares issued in execution of agreement (in shares)	1,276,250
Clinical Collaboration Agreement \| Allist
Agreement
Research and development		700	500
Cost reimbursement		$ 300	$ 400
Milestone payments paid				$ 5,000